We investigated the potential efficacy of treating adult T-cell leukemia (ATL) using a gene therapeutic approach involving the use of a herpes simplex virus-thymidine kinase (HSV-TK)-mediated suicide system. Human immunodeficiency virus (HIV)-based vectors containing the HSV-TK gene were constructed to achieve targeted gene transfer into CD4-positive ATL cells, after which the transduced cells were selectively killed by treatment with ganciclovir (GCV). To examine the utility of HIV vectors in vivo, ATL-NOD-SCID mice were prepared by intraperitoneal injection of 1 Â 10 7 MT2 cells into NK-depleted nonobese diabetic/severely compromised immunodeficient (NOD-SCID) mice. Thereafter, 1 ml of concentrated HIV vector expressing HSV-TK (HXCTKN) or GFP (HXGFP) stock was injected into the intraperitoneal cavity, and GCV was administered twice a day for 5 days. Fluorescence-activated cell sorting (FACS) analysis showed that 7-11% of MT2 or HUT102 cells recovered from the peritoneal cavity were transduced with the HXGFP. After 3 weeks, plasma sIL2-Ra levels were significantly lower in mice administered HXCTKN than in those administered HXGFP. Moreover, HXCTKN-injected mice survived significantly longer than HXGFP-injected mice. Taken together, these findings suggest that HIV vectors could be used for in vivo targeted gene transfer into ATL cells and could thus serve as the basis for the development of effective new therapies for the treatment of ATL.
Adult T-cell leukemia (ATL) is a malignant disease etiologically associated with human T-cell leukemia virus type I 1 and is characterized by elevated numbers of circulating lymphocytes, frequent skin lesions, hepatosplenomegaly, lymphoadenopathy, hypercalcemia and a rapidly fatal terminal clinical course. Indeed, the prognosis of patients with acute-or lymphoma-type ATL is far worse than that of other lymphoid malignancies when they are treated using conventional chemotherapy. 2 A number of approaches to the treatment of acute ATL, including chemotherapy, 3, 4 bone marrow transplantation, 5, 6 nucleoside analogs, 7,8 interferon 9,10 and monoclonal antibodies 11, 12 also have proven ineffective. Consequently, the potential for using gene therapy in the treatment of ATL is now attracting attention. The utility of several gene therapy protocols for the treatment of malignancies are already being evaluated, and clinical trials are currently ongoing. 13, 14 One approach is to transduce cancer cells using a suicide gene such as the bacterial cytosine deaminase gene. 15 Herpes simplex virus-thymidine kinase (HSV-TK) acts by phosphorylating nucleoside analogs such as ganciclovir (GCV) and aciclovir, yielding monophosphorylated molecules. These are then converted into triphosphates that are incorporated into elongating DNA by cellular polymerase during cell division, causing chain termination and eventually cell death. One particularly interesting finding is that HSV-TK-positive tumor cells killed by GCV were lethal to other tumor cells that had not been transduced. For instance, in an in vivo model system, complete regression of inoculated tumors occurred when as few as 10% of the cells were HSV-TK-positive. This phenomenon, which is termed the 'bystander effect,' 16, 17 appears very promising, as it is not necessary to transduce all of the cancer cells within a tumor.
We previously established a set of human immunodeficiency virus type 1 (HIV-1)-based retroviral vectors, 18 which are capable of targeted and highly efficient gene transfer into CD4-positive T cells mediated via the interaction of the HIV envelope glycoprotein gp120 and the cell surface protein CD4. 19 Recently, we have succeeded in targeted gene transfer into primary CD4 positive cells with high efficiency. 20 Because almost all ATL cells express CD4, we hypothesized that we could use an HIV-based vector to target therapeutic genes to ATL cells. To test this idea, we constructed an HIV-based vector containing the (HSV-TK) suicide gene 21 and investigated the potential efficacy of a gene therapy protocol in which ATL was treated using HSV-TK and GCV.
To analyze selective transduction of ATL cells using HIV vectors containing the HSV-TK gene, five human leukemia cell lines (MT2, MT4, HUT102, K562 and Raji) were transduced with an HIV vector containing the HSV-TK gene (HXCTKN) or the empty vector (HXN) ( Figure 1 ) and then selected for 2 weeks with G418. G418-resistant cells were detected only among the CD4-positive MT2, MT4 and HUT102 ATL cell lines. The CD4-negative K562 and Raji cells were not transduced by the HIV vectors (Table 1) . We next used syncytium assays 18 to assess the possibility that replication-competent HIV virus was generated by recombination. MT2 cells are highly sensitive to the cytopathic effects of HIV and form a syncytium as a result of cell-tocell fusion when infected by replication-competent HIV. But when we incubated these cells with concentrated HIV vector for 3 months, we observed no syncytium formation, indicating that with our protocol there was no generation of HIV virus capable of replication. This finding was confirmed by analysis of p24 level using the ELISA kit (ZeptoMetrix Corp., Buffalo, NY, USA). We did not detect the elevation of p24 level in cultured supernatant. When we cultured these HIV vector-transduced and G418 selected cell lines in the presence of different concentrations of GCV, we found that parental and HXNtransduced ATL cells were resistant to the cytotoxicity of GCV. By contrast, the cell viabilities in the presence of 1 mg ml À1 GCV were 41, 37 and 62% in HXCTKNtransduced MT2, MT4 and HUT102 cells (Figure 2 ). Thus GCV-mediated cytotoxicity was detected in HXCTKNtransduced ATL cells.
To determine whether primary ATL cells would also be killed by our HIV vectors, ATL tumor cells from the ascites of an ATL patient were transduced with HIV vector-expressing GFP (HXGFP) or HXCTKN ( Figure 1 ). Subsequent FACS analysis showed that more than 60% of primary ATL cells were transduced by the HXGFP (Figure 3a) . Moreover, the cell viability in the presence of 1 mg ml À1 GCV was 47% among the HXCTKNtransduced primary ATL cells (Figure 3b ). Thus, HIV vector containing HSV-TK gene killed primary ATL cells as well as ATL cell lines.
To examine the utility of HIV vectors in vivo, we prepared ATL model mice by intraperitoneal injection of 1 Â 10 7 MT2 or HUT102 cells into TM-b1-treated SCID/ NOD mice (Jackson Laboratories, Bar Harbor, ME, USA). We used TM-b1 to facilitate the engraftment of ATL cells by depletion of NK cell activity. As ATL tumor cells secrete sIL2-Ra, the presence of ATL cells was confirmed by the high serum sIL2-Ra levels detected in the mice. One microliter of the HIV vector stock (HXGFP n ¼ 7, HXCTKN n ¼ 7; 1-5 Â 10 8 CFU ml À1 ) was then injected into the intraperitoneal cavity, after which GCV was administered twice a day for 5 days. FACS analysis showed that 7-11% of MT2 cells recovered from the peritoneal cavity were transduced with the HXGFP (Figure 4a ). Three weeks later, serum sIL2-Ra levels were significantly lower in mice administered HXCTKN than in those administered control HXGFP (Po0.005) (Figure 4b ). Moreover, mice injected with HXCTKN survived significantly longer than those injected with HXGFP (P ¼ 0.002) (Figure 4c ). We got almost the same results by repeated in vivo experiment. When we also analyzed the survival effect using HUT102 cells (1 Â 10 7 ) injected into ATL model mice, extended survival was detected in HXCTKN-injected mice compared to HXGFP-injected control mice (P ¼ 0.003; Figure 4d ). These results suggest that HIV vector could be used in vivo for targeted gene transfer into ATL cells and that this system may be a useful means of administering gene therapy for the treatment of ATL.
When we injected HIV vector in vivo, 7-11% of MT2 cells recovered from the peritoneal cavity were found to have been transduced. However, we obtained a significant survival effect in HXCTKN-injected mice. Moreover, two of the seven treated mice showed complete rejection Figure 1 The structures of the HIV packaging and vector plasmids: c, packaging signal; RRE, rev response element. Construction of the recombinant HIV packaging plasmid (pCAGgpR and penvBH10) and vector plasmids (pHXN and pHXGFP) was described previously. 18, 20 The pHXCTKN plasmid was constructed by the insertion of a CMV promoter-driven HSV-TK fragment (1.2 kb) containing the HSV-TK coding sequence isolated from plasmid M2 35 into the XhoI site of pHXN. Recombinant HIV vector was generated by transfection of 7 mg of pCAGgpR, penvBH10 and 10 mg of an expression vector (pHXN or pHXCTKN or pHXGFP) into Cos cells (2 Â 10 6 cells in a 10-cm dish) using the CaPO 4 co-precipitation method described previously. 20 The HIV vectors in the conditioned medium were then concentrated by ultrafiltration using CENTRIPREP columns, as described previously, 20 to prepare vector stocks.
Targeted gene therapy for ATL K Miyake et al of the MT2 tumor cells. These effects may reflect the bystander effect, which is characteristic of the HSV-TK/ GCV suicide system and has been observed both in vitro and in vivo. 16, 17 Thanks to this effect, if 10-20% of a mixed-cell population is HSV-TK-positive, nearly all of the cells will be killed. Several possible mechanisms have been proposed to explain the bystander effect, including induction of apoptotic cell death, 22 transfer of toxic molecules through gap junctions 16 and enhancement of the immune response. 23 Using hematopoietic cells, Tiberghien et al. 24 observed that a bystander effect was not seen in HSV-TK-transduced T cells. On the other hand, Dilber et al. 25 reported that a bystander effect occurred in ARH-77 myeloma cell lines, suggesting that whether or not a bystander effect occurs in hematopoietic cells may depend on the specific cell type.
There is ample precedent for the use of viral vectors when employing gene therapy in the treatment of cancer. For instance, the use of Moloney murine leukemia virus to mediate therapeutic gene transfer in the treatment of various malignancies is widely appreciated. [26] [27] [28] [29] In the present study, we demonstrated an HIV-mediated gene transfer system that is potentially useful for the treatment of ATL. The fact that the major receptor for HIV infection is the cell surface molecule CD4 on helper T cells enables HIV vectors to be used for targeted gene The CD4-positive and CD4-negative human leukemia cell lines (1 Â 10 6 ) were incubated for 48 h with 1 ml of conditioned Cos cell medium (HXN or HXCTKN) and 6 mg ml À1 polybrane. Thereafter, cells transduced with HIV vectors were dispensed into 96-well culture plates at a density of 1 Â 10 2 cells per well and incubated for 2 weeks in medium containing G418, after which wells containing G418-resistant cells were counted. 37 Parental cells and HIV vector transductants were seeded in triplicate into 96-well flat-bottomed culture plates to a density of 1 Â 10 4 cells per well. After incubation for 24 h, the medium was replaced with RPMI-10 containing the indicated concentration of ganciclovir (0.01-10 mg ml À1 ), and the cells were incubated for an additional 5 days. Cell Titer 96 substrate was then added without changing the medium, after which the cells were incubated for 2 h at 37 1C and the plates were read at 490 nm using an ELISA plate reader. The results are expressed as percentages of the growth of an untreated control (WT) and presented as means of triplicate experiments7s.d. That said, an essential feature of clinical approaches to cancer gene therapy that make use of the HSV-TK suicide gene is that the gene is expressed exclusively by tumor cells. In several instances, this has been accomplished by using tumorspecific promoters-for example, the a-fetoprotein or liver-associated albumin promoter for hepatocellular carcinoma, 30 the tyrosinase promoter for malignant melanoma 31 and the carcinoembryonic antigen promoter for carcinoembryonic antigen-producing cancer. 32 But although tumor-specific expression was accomplished in these cases, the carrying genes from the viral vectors used were randomly integrated into both normal tissues and the tumors. Consequently, insertional mutagenesis problems, such as the activation of cellular oncogenes and inactivation of tumor suppressor genes in nontarget cells, could occur. 33 With our new system, in which the gene is selectively transferred only into CD4-positive cells, the chance of insertional mutagenesis is very low. In that respect, our approach is superior to those making use of a tumor-specific promoter.
Because HIV-based vectors are capable of targeted gene transfer into all CD4-positive cells, they are capable of transducing normal T cells as well as ATL cells. In vivo, however, the majority of circulating T cells are quiescent, whereas ATL tumor cells are actively dividing. Although HIV vector could potentially transduce cells that are not dividing, the transduction efficiency seen in human T-cell leukemia virus type I-infected cells is substantially Targeted gene therapy for ATL K Miyake et al higher in dividing cells than in quiescent cells. Moreover, cell division is essential for activation of the HSV-TK/ GCV suicide system, 21, 34 which means that it should be active only in ATL cells, enabling it to be used for in vivo targeted gene transfer into ATL cells. Consistent with this idea, we found that ATL tumor cells from ascites, which are often resistant to conventional chemotherapy, were transduced by HXCTKN vectors and subsequently killed upon administration of GCV.
In summary, we have described the use of HIV vectormediated targeted TK/GCV suicide gene therapy in a mouse ATL model generated by an intraperitoneal injection of MT2 or HUT102 cells into NOD-SCID mice. Using this approach, we were able to significantly inhibit ATL cell growth and extend the survival of ATL model mice. It thus appears that HIV vectors could be used for in vivo targeted gene transfer into ATL cells and could also serve as a basis for the development of effective new therapies for the treatment of ATL.
